Olaptesed pegol

DRUG2 trials

Sponsors

TME Pharma AG

Conditions

GlioblastomaMetastatic Pancreatic Cancer

Phase 1

Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients

Active, not recruitingNCT04121455

TME Pharma AGGlioblastoma

Start: 2019-09-12End: 2028-12-31Target: 117Updated: 2025-06-25

Phase 2

Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer

Not yet recruitingNCT04901741

TME Pharma AGMetastatic Pancreatic Cancer

Start: 2026-01-31End: 2029-03-31Target: 60Updated: 2025-06-27

Related Papers

L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial.

2026-04-08

CTNI-18. DUAL INHIBITION OF POST-RADIOGENIC REVASCULARIZATION IN NEWLY-DIAGNOSED GLIOBLASTOMA: FINAL RESULTS OF THE MULTICENTRIC PHASE 1/2 GLORIA TRIAL

Neuro-Oncology2025-11-01

L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial.

2024-05-2832 citations

ALA-RDT in GBM: protocol of the phase I/II dose escalation trial of radiodynamic therapy with 5-Aminolevulinic acid in patients with recurrent glioblastoma

Radiation Oncology2024-01-2217 citations

CTNI-62. INTERIM DATA ON DUAL INHIBITION OF POST-RADIOGENIC ANGIO-VASCULOGENESIS BY OLAPTESED PEGOL (NOX-A12) AND BEVACIZUMAB IN GLIOBLASTOMA FROM THE FIRST EXPANSION ARM OF THE PHASE 1/2 GLORIA TRIAL

Neuro-Oncology2023-11-01

Potential predictive biomarker for response to radiotherapy and CXCL12 inhibition in glioblastoma in the phase I/II GLORIA trial.

Journal of Clinical Oncology2023-06-016 citations

CTNI-67. DUAL INHIBITION OF POST-RADIOGENIC ANGIO-VASCULOGENESIS BY OLAPTESED PEGOL (NOX-A12) AND BEVACIZUMAB IN GLIOBLASTOMA – INTERIM DATA FROM THE FIRST EXPANSION ARM OF THE GERMAN PHASE 1/2 GLORIA TRIAL

Neuro-Oncology2022-11-01

Radiotherapy and olaptesed pegol (NOX-A12) in partially resected or biopsy-only MGMT-unmethylated glioblastoma: Interim data from the German multicenter phase 1/2 GLORIA trial.

Journal of Clinical Oncology2022-06-018 citations

CTNI-43. CXCL12 INHIBITION IN MGMT UNMETHYLATED GLIOBLASTOMA – RESULTS OF AN EARLY PROOF-OF-CONCEPT ASSESSMENT IN THE MULTICENTRIC PHASE I/II GLORIA TRIAL (NCT04121455)

Neuro-Oncology2021-11-02